Shantel
Key Takeaways:
- Modi Ventures, an innovative venture partnership, launches with a $32 million fund, focusing on high-impact early-stage startups and venture funds in Tech Bio, life sciences, and AI.
- Founded by Sahir Ali, a distinguished figure in precision medicine and AI, Modi Ventures aims to revolutionize healthcare and medicine through advanced technologies.
- The fund aims to exploit opportunities in Tech Bio, which uses AI to analyze complex information and create an exponential impact on health and technology.
- Modi Ventures has already established partnerships with successful funds like Khosla Ventures, Section 32, Artis Ventures, Draper Associates, and Antler Group.
The Launch of Modi Ventures
Modi Ventures, a fresh, dynamic venture partnership committed to investing in fund managers and founders at the forefront of shaping humanity’s future, proudly announced the launch of its first $32 million fund, Tech+Bio Fund I. Aimed at innovative companies pioneering transformation in Tech Bio, life science, and healthcare AI, the fund was raised in a brief timeframe, exceeding its goal by $2 million. In a commendable move, Andrew Yang, a former presidential candidate and the founder of Venture for America, has been appointed as an advisor.
Sahir Ali: The Powerhouse Behind Modi Ventures
Modi Ventures is the brainchild of Sahir Ali, a renowned researcher, scientist, and technologist, recognized for his thought leadership in precision medicine and AI. With a Ph.D. focused on the intersection of oncology and AI, Sahir has successfully advised and led F500 companies in the healthcare, AI, and enterprise tech sectors. He affirms, “Investing in next-generation technologies has always been very lucrative. We are entering an era of software writing software (artificial intelligence), technology that can unravel our individual genetic makeup (gene sequencing), biotech that can reprogram our genes (gene editing), and a fundamental change in how medicine is practiced by leveraging all of the above (precision medicine).”
The Mission of Modi Ventures
Modi Ventures’ mission revolves around investing in areas like Tech Bio, where companies are employing exponential technologies at the brink of revolutionizing health and technology. Utilizing AI to analyze complex, heterogeneous information, Tech Bio is disrupting and revolutionizing medical practice and health delivery. This field holds immense potential in transforming clinical trial design, drug development, and precision medicine. With potential direct annual impacts between $2 trillion and $4 trillion, Tech Bio innovations could account for 60% of the world’s physical goods inputs and ease 45% of the world’s disease burden.
Notable Partnerships and Investments
Modi Ventures has fostered robust partnerships with successful funds, including Khosla Ventures, Section 32, Artis Ventures, Draper Associates, and Antler Group. Its initial investments by the Tech+Bio Fund I include Lapsi Health, a medical technology company utilizing sound and auscultation for screening, diagnosing, treating, and monitoring in medicine, Starling Medicine, a predictive technology platform for early detection of bladder health issues, and Cyberdontics, a company harnessing advanced imaging, AI, and robotics for automated dental surgery.
About Modi Ventures
Modi Ventures Capital Management, based in Texas, is an investment firm committed to backing fund managers and founders who are shaping the future of humanity through disruptive AI and medical technology applications. With investments in successful funds like Khosla Ventures, Section 32, Artis Ventures, Draper Associates, and Antler Global, and direct investments in Lapsi Health, Starling Medicine, and Cyberdontics, Modi Ventures is poised to influence the future of healthcare technology. To learn more about Modi Ventures, visit www.modivc.com.
